Urine and serum analysis of consumed curcuminoids using an IκB-luciferase surrogate marker assay

In Vivo

Volumn 24, Issue 6, 2010, Pages 861-864

  Ponnurangam, Sivapriya ^a   Mondalek, Fadee G ^a   Govind, Janita ^a   Subramaniam, Dharmalingam ^b   Houchen, Courtney W ^b   Anant, Shrikant ^b   Pantazis, Panayotis ^a   Ramanujam, Rama P ^a  

^a Swaasth Inc   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Clinical trial; Curcumin; GEM assay; Urinalysis

Indexed keywords

CURCUMIN; CURCUMINOID DERIVATIVE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASSAY; BLOOD ANALYSIS; CELL STRAIN HCT116; CONTROLLED STUDY; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FEMALE; GENE EXPRESSION; GENETIC EXPRESSION AND MEASUREMENT ASSAY; HUMAN; HUMAN CELL; MALE; URINALYSIS;

EID: 78650950783     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Epstein J, Sanderson IR and Macdonald TT: Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 103(11): 1545-1557, 2010.
2. Tamvakopoulos C, Sofianos ZD, Garbis SD and Pantazis P: Analysis of the in vitro metabolites of diferuloylmethane (curcumin) by liquid chromatography - tandem mass spectrometry on a hybrid quadrupole linear ion trap system: newly identified metabolites. Eur J Drug Metab Pharmacokinet 32(1): 51-57, 2007.
3. Baum L, Cheung SK, Mok VC, Lam LC, Leung VP, Hui E, Ng CC, Chow M, Ho PC, Lam S, Woo J, Chiu HF, Goggins W, Zee B, Wong A, Mok H, Cheng WK, Fong C, Lee JS, Chan MH, Szeto SS, Lui VW, Tsoh J, Kwok TC, Chan IH and Lam CW: Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res 56(6): 509-514, 2007.
4. Nafisi S, Adelzadeh M, Norouzi Z and Sarbolouki MN: Curcumin binding to DNA and RNA. DNA Cell Biol 28(4): 201-208, 2009.
5. Jurenka JS: Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 14(2): 141-153, 2009.
6. Takayama T, Goji T, Taniguchi T and Inoue A: Chemoprevention of colorectal cancer-experimental and clinical aspects. J Med Invest 56(1-2): 1-5, 2009.
7. Ono M: Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 99(8): 1501-1506, 2008.
8. Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P, Mantovani A and Sica A: Cellular and molecular pathways linking inflammation and cancer. Immunobiology 214(9-10): 761-777, 2009.
9. Aggarwal BB, Vijayalekshmi RV and Sung B: Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15(2): 425-430, 2009.
10. Barnes PJ and Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336(15): 1066-1071, 1997.
11. Hanai H and Sugimoto K: Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des 15(18): 2087-2094, 2009.
12. Pantazis P, Varman A, Simpson-Durand C, Thorpe J, Ramalingam S, Subramaniam D, Houchen C, Ihnat M, Anant S and Ramanujam RP: Curcumin and turmeric attenuate arsenic-induced angiogenesis in ovo. Altern Ther Health Med 16(2): 12-14, 2010.
13. Lao CD, Ruffin MTt, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL and Brenner DE: Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6: 10, 2006.
14. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z and Brenner DE: Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 17(6): 1411-1417, 2008.
15. Subramaniam D, Ramalingam R, Betz J, Murali P, Houchen C and Anant S: A novel in vitro method to determine the bioactivity of phytochemicals in botanical extracts. Found Med Res 44-56, 2006.
16. Mondalek FG, Ponnurangam S, Govind J, Houchen C, Anant S, Pantazis P and Ramanujam RP: Inhibition of angiogenesis- and inflammation-inducing factors in human colon cancer cells in vitro and in ovo by free and nanoparticle- encapsulated redox dye, DCPIP. J Nanobiotechnology 8: 17, 2010.
17. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ and Steward WP: Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10(20): 6847-6854, 2004.